Latest Manufacturing News

Dimerix has strengthened its kidney disease pipeline with a US patent grant for DMX-652, extending protection until 2043 and setting the stage for a Phase 2 trial targeting acute kidney injury after cardiac surgery.

Generation Development Group (ASX: GDG) closed FY26 with a 36% jump in funds under management to $46.4 billion, powered by record sales at Generation Life and a landmark strategic partnership with Colonial First State.

PolyNovo has delivered solid FY26 revenue growth of 16.1%, driven by commercial sales expansion and improved manufacturing output, while progressing insurance recovery from its R&D centre fire.

Vitrafy Life Sciences has partnered with the historic Hoxworth Blood Center to deploy its next-generation cryopreservation technology, aiming to address a critical gap in red blood cell preservation ahead of legacy technology discontinuation in 2027.

Bayan Mining has agreed to sell its Bayan Springs North Project in Nevada to Sun Silver for up to A$800,000, retaining a 1.0% royalty and securing non-dilutive funding to focus on rare earths development.

Tourism Holdings Limited has upgraded its FY26 underlying net profit after tax to around $46 million, beating earlier guidance. The company reports strong vehicle sales in New Zealand and robust late bookings, particularly in North America, while net debt ended lower than expected.

Yowie Group’s latest quarters reveal falling revenues and shrinking cash reserves, even as new leadership and product launches aim to stabilise the confectionery maker’s turnaround.

Papyrus Australia has tapped related party L39 Capital to lead a capital raise and secured an interest-bearing $200,000 loan from Irwin Biotech, with conversion into shares and options pending shareholder approval.

Amaero Inc. capped FY2026 with a record A$18.1 million revenue, expanded its production capacity, and landed a A$6.5 million US Department of War contract to develop alternative refractory alloy powders.

Lynas Rare Earths posted a record A$288.9 million in quarterly sales for Q4 FY26, driven by higher prices and heavy rare earth sales. The company advanced its Malaysia heavy rare earth facility despite a cost surge and appointed Pol Le Roux as interim CEO.

RocketDNA reported a 52% year-on-year revenue increase and expanded its autonomous drone operations with four new enterprise customers in Q2 FY26. The company also advanced software integration with Deswik to embed drone data into mine-planning workflows.

Entropy Neurodynamics has reported breakthrough Phase 2 clinical results for its intravenous psilocin therapy in treatment-resistant Binge Eating Disorder, alongside strong Phase 2a data in Irritable Bowel Syndrome and a new US patent filing.